Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells

OncoImmunology

Volumn 4, Issue 9, 2015, Pages 1-11

  Ames, Erik ^a   Canter, Robert J ^a   Grossenbacher, Steven K ^a   Mac, Stephanie ^a   Smith, Rachel C ^a   Monjazeb, Arta M ^a   Chen, Mingyi ^a   Murphy, William J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adoptive immunotherapy; Cancer stem cell; Natural killer cells; Radiotherapy

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; RECOMBINANT INTERLEUKIN 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RADIATION DOSE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SOLID TUMOR; TISSUE MICROARRAY; TUMOR GROWTH; UPREGULATION;

EID: 84944454301     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1036212     Document Type: Article

References (35)

1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60; PMID:17051156; http://dx.doi.org/ 10.1038/nature05236
2. Bensimon J, Altmeyer-Morel S, Benjelloun H, Chevillard S, Lebeau J. CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability. Oncogene 2013; 32:251-8; PMID:22330142; http://dx.doi.org/10.1038/onc. 2012.31
3. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumorinitiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PloS One 2011; 6:e20636; PMID:21695188; http://dx.doi.org/ 10.1371/journal.pone.0020636
4. Rasheed Z, Wang, Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010; 43:pii: 2169; PMID:20972397; http://dx.doi. org/10.3791/2169
5. AwadO, Yustein JT, Shah P,Gul N, KaturiV, O'NeillA, Kong Y, BrownML, Toretsky JA, Loeb DMHigh ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PloS One 2010; 5:e13943; PMID:21085683; http://dx. doi.org/10.1371/journal.pone.0013943
6. Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PloS One 2012; 7: e43664; PMID:22928012; http://dx.doi.org/10.1371/ journal.pone.0043664
7. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010; 24: 501-5; PMID:20596639; http://dx.doi.org/10.3892/ or_00000885
8. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.org/10.1016/j. stem.2007.08.014
9. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29:32-45; PMID:21280157; http://dx.doi.org/ 10.1002/stem.563
10. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13:2236-52; PMID:18681906; http://dx.doi.org/10.1111/j.1582-4934.2008.00455.x
11. Singh SKHawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401; PMID:15549107; http:// dx.doi.org/10.1038/nature03128
12. Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ et al. Antiproliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 2014; 14:756; PMID:25301268; http://dx. doi.org/10.1186/1471-2407-14-756
13. Wang WJ, Wu SP, Liu JB, Shi YS, Huang X, Zhang QB, Yao KT. MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells. Cancer Res 2013; 73(3):1219-31; PMID:23269272; http://dx.doi.org/10.1158/0008-5472
14. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004; 104:2940-42; PMID:15251980; http://dx.doi.org/10.1182/ blood-2004-04-1398
15. Barcellos-Hoff MH, Park C., & Wright E.G. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev. Cancer 2005; 5:867-75; PMID:16327765; http://dx.doi.org/10.1038/nrc1735
16. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Investig 2013; 123:2756-63; PMID:23863633; http:// dx.doi.org/10.1172/JCI69219
17. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/ 10.1056/NEJMoa1112824
18. HallettWH,MurphyWJ. Positive and negative regulation of Natural Killer cells: therapeutic implications. Semin Cancer Biol 2006; 16:367-82; PMID:16934486; http:// dx.doi.org/10.1016/j.semcancer.2006.07.003
19. Perez-Cunningham J, Ames E, Smith RC, Peter AK, Naidu R, Nolta JA, Murphy WJ. Natural killer cell subsets differentially reject embryonic stem cells based on licensing. Transplantation 2014; 97:992-8; PMID:24704665; http://dx.doi.org/10.1097/ TP.0000000000000063
20. Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother 2014; 63:21-8; PMID:23989217; http://dx.doi.org/10.1007/s00262-013-1469-8
21. Vivier E, Tomasello E, Baratin M,Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/ 10.1038/ni1582
22. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011; 89:216-24; PMID:20567250; http://dx.doi.org/10.1038/ icb.2010.78
23. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cellassociated antigens. Stem Cells 2009; 27:1734-40; PMID:19536809; http://dx.doi.org/10.1002/stem.102
24. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010; 16:800-13; PMID:20103663; http://dx.doi.org/10.1158/1078-0432.CCR-09-2730
25. Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, Zhang G, Albers AE. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol 2013; 139:159-170; PMID:23001491; http://dx.doi.org/10.1007/s00432-012-1311-2
26. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010; 7:279-82; PMID:20804964; http://dx.doi.org/10.1016/j. stem.2010.08.009
27. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PloS One 2009; 4:e8377; PMID:20027313; http://dx.doi.org/10.1371/journal. pone.0008377
28. Al-Hajj M, Wicha MS, Benito-Hernandez, A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-88; PMID:12629218; http://dx.doi. org/10.1073/pnas.0530291100
29. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M et al. Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2015; 33(7):786-809; PMID:25605863; http://dx.doi. org/10.1200/JCO.2014.59.9746
30. Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013; 190:2381-90; PMID:23345327; http://dx.doi.org/10.4049/jimmunol.1201542
31. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100:1935-47; PMID:12200350; http://dx.doi. org/10.1182/blood-2002-02-0350
32. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cellbased immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http:// dx.doi.org/10.1038/cmi.2013.10
33. Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, Xu C et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res 2014; 74:5746-57; PMID:25164008; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-2563
34. Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ. Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood 2013; 122:1518-21; PMID:23818546; http://dx.doi.org/10.1182/blood-2013-02-483503
35. Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17:1754-64; PMID:21906575; http://dx.doi.org/10.1016/j. bbmt.2011.08.023